Role of Bismuth in the Eradication of Helicobacter pylori.

Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9441347 Publication Model: Print Cited Medium: Internet ISSN: 1536-3686 (Electronic) Linking ISSN: 10752765 NLM ISO Abbreviation: Am J Ther Subsets: MEDLINE

Publication: 1998- : Philadelphia, PA : Lippincott Williams & Wilkins
Original Publication: New York, NY : Chapman & Hall, c1994-

Antacids/*therapeutic use ; Anti-Bacterial Agents/*therapeutic use ; Bismuth/*therapeutic use ; Disease Eradication/*methods ; Helicobacter Infections/*prevention & control ; Helicobacter pylori/*drug effects; Antacids/pharmacology ; Anti-Bacterial Agents/pharmacology ; Bismuth/pharmacology ; Clarithromycin/pharmacology ; Clarithromycin/therapeutic use ; Drug Resistance, Bacterial/drug effects ; Drug Therapy, Combination/methods ; Drug Therapy, Combination/standards ; Gastric Mucosa/drug effects ; Gastric Mucosa/metabolism ; Helicobacter Infections/microbiology ; Helicobacter pylori/isolation & purification ; Helicobacter pylori/physiology ; Humans ; Metronidazole/pharmacology ; Metronidazole/therapeutic use ; Peptic Ulcer/drug therapy ; Peptic Ulcer/microbiology ; Practice Guidelines as Topic ; Proton Pump Inhibitors/pharmacology ; Proton Pump Inhibitors/therapeutic use ; Ranitidine/pharmacology ; Ranitidine/therapeutic use

Bismuth salts exert their activity within the upper gastrointestinal tract through action of luminal bismuth. Bismuth exerts direct bactericidal effect on Helicobacter pylori by different ways: forms complexes in the bacterial wall and periplasmic space, inhibits different enzymes, ATP synthesis, and adherence of the bacteria to the gastric mucosa. Bismuth also helps ulcer healing by acting as a barrier to the aggressive factors and increasing mucosal protective factors such as prostaglandin, epidermal growth factor, and bicarbonate secretion. To date, no resistance to bismuth has been reported. Also synergism between bismuth salts and antibiotics was present. It was shown that metronidazole and clarithromycin resistant H. pylori strains become susceptible if they are administered together with bismuth. Bismuth-containing quadruple therapy was recommended both by the Second Asia-Pacific Consensus Guidelines and by the Maastricht IV/Florence Consensus Report as an alternative first choice regimen to standard triple therapy, in areas with low clarithromycin resistance, and it is recommended as the first-line therapeutic option in areas with a high prevalence of clarithromycin resistance. Greater than 90% eradication success can be obtained by bismuth-containing quadruple therapy. Choosing bismuth as an indispensable part of first-line therapy is logical as both metronidazole and clarithromycin resistances can be overcome by adding bismuth to the regimen.

0 (Antacids)
0 (Anti-Bacterial Agents)
0 (Proton Pump Inhibitors)
140QMO216E (Metronidazole)
884KT10YB7 (Ranitidine)
H1250JIK0A (Clarithromycin)
U015TT5I8H (Bismuth)

Date Created: 20160126 Date Completed: 20180621 Latest Revision: 20181202

20221213

10.1097/MJT.0000000000000389

26808355